Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Mechanism of action

1 evidence topic · 1 source

Mechanism of action

“Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.” (opens the prescribing information at this quote)

“LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.” (opens the prescribing information at this quote)